Long-Acting Obesity Treatment with SmartDepot Technology Enters Official Clinical Stage
Development of Once-Monthly Semaglutide Formulation Signals Intensified Competition for Dosing Convenience
Development Accelerates Following ADA 2026 Pilot Clinical Trial

Peptron, a peptide-based novel drug development company, announced on August 25 that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety for its long-acting obesity treatment PT403, which is administered once monthly and uses the company’s extended-release drug delivery platform, SmartDepot™.

PeptroN company logo image. PeptroN

PeptroN company logo image. PeptroN

View original image

This Phase 1 clinical trial aims to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of a single subcutaneous dose of PT403 in 22 healthy adults. The study will be conducted at Chungnam National University Hospital’s Clinical Trial Center, using a randomized, double-blind, placebo-controlled, active reference, parallel-group, dose-escalation design. The trial consists of three cohorts, and subsequent dose groups will only proceed after the Safety Review Committee (SRC) reviews the safety and tolerability data from the previous group.


PT403 is a long-acting injectable drug being developed to extend the current weekly dosing schedule of semaglutide to a once-monthly injection, utilizing Peptron’s SmartDepot technology.


In the global obesity treatment market, “dosing schedule extension,” which reduces the frequency of administration to improve long-term treatment convenience and adherence, is emerging as a key competitive factor in addition to weight reduction efficacy. Unlike new compound development, PT403 leverages semaglutide—an active pharmaceutical ingredient (API) with established clinical and commercialization experience—by adapting it into a long-acting formulation. Through this clinical trial, Peptron plans to evaluate the unique safety, tolerability, and pharmacokinetic profile of PT403 itself.


This IND submission marks Peptron’s official entry into the clinical development stage for PT403, following the preclinical and pilot clinical results presented at the American Diabetes Association (ADA 2026) conference in June. At that time, the company announced results from a pilot clinical trial, where eight subjects received PT403 and eight received conventional semaglutide, confirming the initial pharmacokinetic, safety, and tolerability profile for PT403.



A Peptron representative stated, “The competitive landscape in the global obesity treatment market is expanding from a focus on weight-loss efficacy to include product strengths suitable for long-term therapy, such as dosing convenience and treatment adherence. PT403 is being developed to enable once-monthly administration of semaglutide using our SmartDepot technology.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing